|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement?
|
| Published Date:
June 2009
Published By:
Decision Resources
Page Count:
37
Order Code:
R55-650
|
|
|
|
Introduction
For decades, the efficacy of hormone replacement therapy (HRT) for some of menopause’s most
troublesome symptoms eliminated any incentive to develop new approaches to treatment. However,
data questioning the safety of estrogen-containing therapies have galvanized researchers and drug
developers to begin investigating new mechanisms to treat menopausal symptoms that can capitalize
on the newly realized need for safer treatment options, although these agents will still be challenged
by the efficacy of HRTs.
Questions Answered in This Report
- Menopause is a natural process of aging that is accompanied b • y substantial hormonal changes.
What are the symptoms of menopause? What are the causes of these symptoms? What are the
current treatment options? What are the benefits and drawbacks of these treatments?
- Data from the Women’s Health Initiative suggest that estrogen therapy is not suitable for all women.
What are the risks associated with hormone therapy? Do emerging agents offer safer or more
efficacious treatment approaches?
- With the final wave of baby boomers reaching menopausal age, the menopause treatment patient
population is on the rise. What were the sales of menopausal symptom treatments in 2008? How
well will emerging agents address the remaining needs in this market? How will emerging
agents fit into the treatment algorithm in the future?
Scope
- Overview of menopause: Physiology and symptoms.
- Current treatments: Hormone replacement therapy, selective estrogen receptor
modulators, SSRIs/SNRIs, gabapentin.
- Emerging treatments: Wyeth’s Pristiq, Wyeth’s bazedoxifene/conjugated estrogens,
Depomed’s controlled-release gabapentin, Schering-Plough’s esmirtazapine.
- Outlook: 2008 market, challenges and opportunities, the potential of emerging agents, the
future of HRT.
- Women’s Health Series: This report is part of Spectrum’s Women’s Health Series, which
focuses on areas of unmet need and the best marketing strategies to ensure adoption of a
new agent into the market for women’s reproductive health—a sector that exceeded $23
billion in 2007.
|
Similar Products
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
• Plunkett's Health Care Technologies Overview 2010 (Summary)
Published Oct 2009 by Plunkett Research, Ltd.
• Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
Published Oct 2009 by Datamonitor
• Commercial Insight: Parkinson's Disease - Japan and Europe to drive total market growth
Published Oct 2009 by Datamonitor
• Commercial Insight: Antidepressants - Novel mechanism offers hope in depressed market
Published Oct 2009 by Datamonitor
• Parkinson's Disease Market Forecast
Published Oct 2009 by Datamonitor
• Orphan Drug Strategies
Published Oct 2009 by Datamonitor
• Pipeline Insight: HIV - The Age of Convenience
Published Oct 2009 by Datamonitor
• The World Market for Addiction Disorders, 2009 - 2016
Published Oct 2009 by Spectra Intelligence
|
|
|
|
0 items
